DBV to start Phase II trial of peanut allergy immunotherapy
This article was originally published in Clinica
French firm DBV Technologies is to begin a Phase II study of its VIASKIN Peanut product, for patients with peanut allergy, in mid-2011. The trial has just been recommended by the US Consortium of Food Allergy Research. It will be funded by a five-year grant from the US National Institutes of Health, and will take at least three years. VIASKIN Peanut is designed to desensitise people with peanut allergies by safely exposing them to the allergen through their skin without breaking the blood-skin barrier. This could avoid systemic shock, which is a concern with other desensitisation therapies, DBV says. Eventually, the product should increase the amount of peanuts that patients can consume without experiencing symptoms.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.